健康な高齢者におけるビタミンEサプリメントとインビボ免疫応答. ランダム化された制御試験です
S N Meydani1, M Meydani, J B Blumberg
1Nutritional Immunology Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA. SvMeydanivIM@HNRC.TUFTS.EDU
JAMA
|May 7, 1997
まとめ
ビタミンEのサプリメントは,健康な高齢者の細胞媒介免疫を改善しました. 200 mg/日投与量は,免疫反応を著しく強化し,有害効果を示さず,より高いビタミンEレベルが高齢者の免疫機能に有益であることを示唆しました.
科学分野:
- 免疫学 免疫学とは
- ゲロントロジーはゲロントロジーの学科です.
- 栄養科学とは,栄養科学である.
背景:
- 老化は,細胞媒介免疫の低下と関連しています.
- ビタミンEは抗酸化物質であり,潜在的に免疫調節効果があります.
- 高齢者の免疫機能を最適化することは,健康と病気の予防に不可欠です.
研究 の 目的:
- 健康な高齢者の細胞媒介免疫のインビボ測定に対するビタミンEサプリメントの長期的な効果を調査する.
- 免疫強化のための最適な用量を決定するために.
主な方法:
- ランダム化,ダブルブラインド,プラセボ対照試験で,65歳以上の88人の健康な被験者を対象とした.
- ビタミンE (60,200,または800 mg/日) またはプラセボを235日間摂取した.
- 評価された遅延型過敏性 (DTH) 皮膚反応とワクチンに対する抗体位 (B型肝炎,デタヌス,ディフテリア,肺炎球菌).
主要な成果:
- ビタミンEの補給,特に1日200mgは,B型肝炎とデタックスワクチンに対するDTH応答と抗体位を著しく改善しました.
- 血清アルファトコフェロール濃度の上昇は,抗体反応とDTHの強化と相関していた.
- ディフテリアに対する抗体タイター,免疫グロブリンレベル,T/B細胞数,または自己抗体レベルに有意な影響は見られなかった.
結論:
- 現在推奨されるより高い用量でのビタミンEサプリメントは,健康な高齢者のT細胞媒介免疫機能を高めることができます.
- 1日200mgの投与量は,特定の免疫マーカーの改善に有効であるようです.
- 副作用は認められず,好ましい安全性プロファイルを示唆しています.
関連する概念動画
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...


